IpiNovyx Bio logo

IpiNovyx Bio

We are a drug platform focused on treating autoimmune and inflammatory diseases.

6 employees · est. 2021 · United States

VS
VentiRx Pharmaceuticals logo

VentiRx Pharmaceuticals

Advancing healthcare innovations with targeted therapies for cancer, respiratory, and autoimmune diseases.

est. 2006

VentiRx Pharmaceuticals is the older company (2021 vs 2006).

Side-by-Side Comparison

IpiNovyx Bio VentiRx Pharmaceuticals
Founded
2021 2006 older
Headquarters
United States Not tracked yet
Employees
6 Not tracked yet
Industry
Biopharma, Biotechnology, Health Care Biotechnology, Health Care, Health and Wellness
Funding Stage
Seed Series B
Total Funding
$10.00M $104.50M
Funding Rounds
2 4
Services
Not tracked yet Not tracked yet
Target Customers
Not tracked yet Not tracked yet
Taxonomy
Autoimmune Diseases, Inflammatory Diseases, Biopharmaceuticals, Small Molecule Therapeutics, Immunoproteasome Modulation, Immunoproteasome Inhibitors, Selective Drug Targeting, Immune Cell Modulation, Selective Inhibition, Therapeutic Development, Precision Medicine, Drug Discovery, Clinical Validation, Biotechnology Innovations, Healthcare Advancement Biopharmaceutical, Clinical-stage, Cancer Treatment, Respiratory Diseases, Autoimmune Diseases, Small Molecule Therapies, TLR8 Agonists, TLR8 Antagonists, Vaccine Adjuvants, Oncology, Allergy Treatment, Immune Response Stimulation, Celgene Corporation Collaboration, Seattle Headquarters, San Diego Operations
Website
ipinovyxbio.com ventirx.com
IpiNovyx Bio logo

About IpiNovyx Bio

IpiNovyx Bio, founded in 2021, is a promising startup in the Biopharma and Biotechnology sectors, with a specific focus on Health Care. The company is headquartered in the United States. Embodying the slogan, "We are a drug platform focused on treating autoimmune and inflammatory diseases," IpiNovy...

VentiRx Pharmaceuticals logo

About VentiRx Pharmaceuticals

VentiRx Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer, respiratory, and autoimmune diseases. The company's product pipeline includes VTX-2337, a small molecule TLR8 agonist designed to stimulate myeloid dendritic cells and monocytes...

We will tell you when either one moves

BounceWatch watches IpiNovyx Bio and VentiRx Pharmaceuticals for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.

Watch both — free

Funding, hiring, leadership and stack changes at IpiNovyx Bio and VentiRx Pharmaceutical... — by email.

Frequently Asked Questions

IpiNovyx Bio — We are a drug platform focused on treating autoimmune and inflammatory diseases.. VentiRx Pharmaceuticals — Advancing healthcare innovations with targeted therapies for cancer, respiratory, and autoimmune diseases.. Both companies operate in related markets but may differ in funding stage, team size, and product focus.
IpiNovyx Bio has raised $10.00M while VentiRx Pharmaceuticals has raised $104.50M.
IpiNovyx Bio and VentiRx Pharmaceuticals operate in overlapping markets and are frequently compared. Track both companies on Bounce Watch to monitor their growth signals in real time.

Compare IpiNovyx Bio with someone else

Start typing a company name or domain.

Related Comparisons

Compiled from the BounceWatch company index. We last looked at IpiNovyx Bio on 11 Mar 2026, and VentiRx Pharmaceuticals on 12 Sep 2024. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

One analytics cookie (Google Analytics). Cookie Policy